Founded in 1998, Indegene Limited provides digital services for the life sciences industry. They assist with drug development, clinical trials, regulatory submissions, pharmacovigilance, complaints management, and sales/marketing support. The company's services can be divided into following categories Enterprise Commercial Solutions Omnichannel Activation Enterprise Medical Solutions Enterprise Clinical Solutions and consultancy services The subsidiary of the company, DT Associates Limited, provides consulting services under the "DT Consulting" brand. It helps life sciences companies manage their digital transformation efforts to ensure continued success in customer experience. The company received the Platinum Level award at the 2023 Healthy Workplace Conference and Awards, a recognition given by Arogya World India Trust in partnership with the Public Health Foundation of India. As of December 31, 2023, the company had 65 clients actively engaged with its services. As of December 31, 2023, the company employed 5,181 people worldwide. Of these, 4,461 are based in India, 530 work in North America, 105 in Europe, 73 in China, and 12 in other regions. Indegene IPO is a book built issue of Rs 1,841.76 crores. The issue is a combination of fresh issue of 1.68 crore shares aggregating to Rs 760.00 crores and offer for sale of 2.39 crore shares aggregating to Rs 1,081.76 crores. Indegene IPO opens for subscription on May 6, 2024 and closes on May 8, 2024. The allotment for the Indegene IPO is expected to be finalized on Thursday, May 9, 2024. Indegene IPO will list on BSE, NSE with tentative listing date fixed as Monday, May 13, 2024. Indegene IPO price band is set at ₹430 to ₹452 per share. The minimum lot size for an application is 33 Shares. The minimum amount of investment required by retail investors is ₹14,916. The minimum lot size investment for sNII is 14 lots (462 shares), amounting to ₹208,824, and for bNII, it is 68 lots (2,244 shares), amounting to ₹1,014,288. For Any Query Call @ +91 9368710882 Open 100% Free Paperless Demat Account @ http://bit.ly/2OuyXNJ More Info Visit @ http://bit.ly/33yTc0V Visit @ https://rmoneyindia.com/ Facebook @ https://www.facebook.com/raghunandanmoneyindia Twitter @ https://twitter.com/Rmoneyindia Linkedin @ https://www.linkedin.com/company/3580395/admin/ #indegeneipo #indegeneiporeview #indegeneipodetails #indegenecompanyreviews #indegenelimited #indegeneipogmp #indegeneipo #indegeneiporeview #indegeneipodetails #ipo #ipolistingloss #ipoapplyoravoid #ShouldyoubuyIPOsonlistingday? #investinipoonlistingday #buyipoonlistingday #buyipoafter1year #valueresearchdata #ipolistingdata #ipoprofitsdata #latestiponews #ipolatestnews #upcomingipo #initialpublicoffering #stockmarket #stockmarketnews indegene ipo, indegene ipo review, indegene ipo details, indegene company reviews, indegene limited, indegene ipo gmp, indegene ipo, indegene ipo review, indegene ipo details, ipo, ipo listing loss, ipo apply or avoid, Should you buy IPOs on listing day?, invest in ipo on listing day, buy ipo on listing day, buy ipo after 1 year, value research data, ipo listing data, ipo profits data, latest ipo news, ipo latest news, upcoming ipo, initial public offering, stock market, stock market news,
Ensure the security of your investments by updating your nominee details in your trading & demat account online. It’s quick and hassle-free!
📌 Act Now to Stay Compliant
For assistance, contact our Customer Care at 0562‑4266666 and email askus@rmoneyindia.com.
IT'S TIME TO HAVE SOME FUN!
Your family deserves this time more than we do.
Share happiness with your family today & come back soon. We will be right here.
Investment to ek bahana hai,
humein to khushiyon ko badhana hai.
E-mail
askus@rmoneyindia.com
Customer Care
+91-9568654321